Implication Of Character Traits In Adherence To Treatment In People With Gout: A Reason For Considering Nonadherence As A Syndrome

References

• WHO. Adherence to Long-Term Therapies. Evidence for Action. Geneva: World Health Organization; 2003.
   Google Scholar
• Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166:348–354. doi:10.1093/aje/kwm07017504779
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009;47:334−341. doi:10.1097/MLR.0b013e31818afa1c19194337
   PubMed Web of Science ®Google Scholar
• Reach G, Michault A, Bihan H, Paulino C, Cohen R, Le Clesiau H. Patients’ impatience is an independent determinant of poor diabetes control. Diabetes Metab. 2011;37:497−504. doi:10.1016/j.diabet.2011.03.00421550831
   PubMed Web of Science ®Google Scholar
• Lebeau G, Consoli SM, Le Bouc R, et al. Delay discounting of gains and losses, glycemic control and therapeutic adherence in type 2 diabetes. Behav Processes. 2016;132:42−48. doi:10.1016/j.beproc.2016.09.00627663668
   PubMed Web of Science ®Google Scholar
• Reach G. Obedience and motivation as mechanisms for adherence to medication: a study in obese type 2 diabetic patients. Patient Prefer Adherence. 2011;5:523−531.22114466
   PubMed Web of Science ®Google Scholar
• Reach G, Pellan M, Crine A, Touboul C, Ciocca A, Djoudi Y. Holistic psychosocial determinants of adherence to medication in people with type 2 diabetes. Diabetes Metab. 2018;S1262-3636(18)30116–2. doi:10.1016/j.diabet.2018.06.001
   Web of Science ®Google Scholar
• Reach G, Boubaya M, Brami Y, Lévy V. Disruption in time projection and non-adherence to long-term therapies. Patient Prefer Adherence. 2018;12:2363−2375.30519002
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29−42. doi:10.1136/annrheumdis-2016-20970727457514
   PubMed Web of Science ®Google Scholar
• Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010;22:165–172. doi:10.1097/BOR.0b013e328335ef3820035225
   PubMed Web of Science ®Google Scholar
• Choi YK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men. The Health Professionals Follow-up Study. Arch Intern Med. 2005;165:742−748. doi:10.1001/archinte.165.7.74215824292
   PubMed Web of Science ®Google Scholar
• Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–447. doi:10.1016/j.amjmed.2006.06.04017466656
   PubMed Web of Science ®Google Scholar
• Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008–3011. doi:10.1001/jama.1991.034702100760361820474
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900. doi:10.1161/CIRCULATIONAHA.107.70338917698728
   PubMed Web of Science ®Google Scholar
• Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937–943. doi:10.1002/(ISSN)1529-013115022337
   PubMed Web of Science ®Google Scholar
• Roddy E, Zhang W, Doherty M, et al. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66:1311–1315. doi:10.1136/ard.2007.07075517504843
   PubMed Web of Science ®Google Scholar
• Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57:822–829. doi:10.1002/(ISSN)1529-013117530682
   PubMed Web of Science ®Google Scholar
• McNabb WL. Adherence in diabetes: can we define it and can we measure it? Diabetes Care. 1997;20:216−218. doi:10.2337/diacare.20.2.215
   Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437−443. doi:10.1592/phco.28.4.43718363527
   PubMed Web of Science ®Google Scholar
• Yin R, Li L, Zhang G, et al. Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis. BMJ Open. 2018;8(4):e017542. doi:10.1136/bmjopen-2017-017542
   PubMed Web of Science ®Google Scholar
• Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence. 2017;11:795−800. doi:10.2147/PPA28458524
   PubMed Web of Science ®Google Scholar
• Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78(5):456−459. doi:10.1016/j.jbspin.2011.05.01021724443
   PubMed Web of Science ®Google Scholar
• Halpern R, Mody RR, Fuldeore MJ, et al. Impact of non compliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25:1711–1719. doi:10.1185/0300799090301796619485724
   PubMed Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321–325. doi:10.1002/art.2040515188314
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356–360. doi:10.1002/(ISSN)1529-013112209479
   PubMed Web of Science ®Google Scholar
• Reach G. A novel conceptual framework for understanding the mechanism of adherence to long term therapies. Patient Prefer Adherence. 2008;2:7–19.19920939
   PubMedGoogle Scholar
• Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. Evaluation de l’observance du traitement anti-hypertenseur par un questionnaire: mise au point et utilisation dans un service spécialisé. Presse Med. 2001;30:1044−1048.11471275
   PubMed Web of Science ®Google Scholar
• Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631−637. doi:10.1016/j.jpsychores.2005.10.02016731240
   PubMed Web of Science ®Google Scholar
• Reach G. Temporality in chronic diseases and adherence to long-term therapies: from philosophy to science and back. Diabetes Metab. 2018;S1262-3636(18)30217–9. doi:10.1016/j.diabet.2018.11.002
   Web of Science ®Google Scholar
• Reach G. The Mental Mechanisms of Adherence to Long-Term Therapies, Mind and Care. Foreword by Pascal Engel. Philospohy and Medicine Springer; 2015.
   Google Scholar
• Fredslund EK, Mørkbak MR, Gyrd-Hansen D. Different domains - Different time preferences? Soc Sci Med. 2018;207:97−105. doi:10.1016/j.socscimed.2018.04.05229734060
   PubMed Web of Science ®Google Scholar
• Williams AF, Wechsler H. Interrelationship of preventive actions in health and other areas. Health Serv Rep. 1972;87:969–976. doi:10.2307/45947044650413
   PubMedGoogle Scholar
• Mohamed N, Mohd Yusoff MF, Isah N, Othman I, Syed Rahim SA, Paiman N. Analysis of factors associated with seatbelt wearing among rear passengers in Malaysia. Int J Inj Contr Saf Promot. 2011;18:3–10. doi:10.1080/17457300.2010.48715320496187
   PubMed Web of Science ®Google Scholar
• Brehm JW. A Theory of Psychological Reactance. New York: Academic Press; 1966.
   Google Scholar
• Brandt S, Dickinson B. Time and risk preferences and the use of asthma controller medications. Pediatrics. 2013;131:e1204–e1210. doi:10.1542/peds.2011-298223478866
   PubMed Web of Science ®Google Scholar
• Weller RE, Cook EWIII, Aswar KB, Cox JE. Obese women show greater delay discounting than healthy-weight women. Appetite. 2008;51:563−569. doi:10.1016/j.appet.2008.04.01018513828
   PubMed Web of Science ®Google Scholar
• Ikeda S, Kang MI, Ohtake F. Hyperbolic discounting, the sign effect, and the body mass index. J Health Econ. 2010;29:268–284. doi:10.1016/j.jhealeco.2010.01.00220167384
   PubMed Web of Science ®Google Scholar
• Perry JL, Carroll ME. The role of impulsive behavior in drug abuse. Psychopharmacology. 2008;200:1−26. doi:10.1007/s00213-008-1173-018600315
   PubMed Web of Science ®Google Scholar
• Shulman EP, Smith AR, Silva K, et al. The dual systems model: review, reappraisal, and reaffirmation. Dev Cogn Neurosci. 2016;17:103−117. doi:10.1016/j.dcn.2015.12.01026774291
   PubMed Web of Science ®Google Scholar
• Christakou A, Brammer M, Rubia K. Maturation of limbic corticostriatal activation and connectivity associated with developmental changes in temporal discounting. NeuroImage. 2010. doi:10.1016/j.neuroimage.2010.08.067
   Web of Science ®Google Scholar
• Gabbay J, Le May A. Evidence based guidelines or collectively constructed “mindlines?” Ethnographic study of knowledge management in primary care. BMJ. 2004;329:1013−1017. doi:10.1136/bmj.329.7473.101315514347
   PubMed Web of Science ®Google Scholar
• Cutolo M, Cimmino MA, Perez-Ruiz F. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Eur Rev Med Pharmacol Sci. 2017;21:4186−4195.29028079
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11:R46. doi:10.1186/ar265919327147
   PubMed Web of Science ®Google Scholar
• Ahmed AT, Karter AJ, Liu J. Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours. Diabet Med. 2006;23:795−802. doi:10.1111/dme.2006.23.issue-716842486
   PubMed Web of Science ®Google Scholar
• Solberg LI, Desai JR, O’Connor PJ, et al. Diabetic patients who smoke: are they different? Ann Fam Med. 2004;2:26–32. doi:10.1370/afm.3615053280
   PubMed Web of Science ®Google Scholar
• Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15. doi:10.1136/bmj.38875.675486.5516790458
   PubMed Web of Science ®Google Scholar
• Pressman A, Avins AL, Neuhaus J, Ackerson L, Rudd P. Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST). Contemp Clin Trials. 2012;33(3):492−498. doi:10.1016/j.cct.2011.12.00322265975
   PubMed Web of Science ®Google Scholar
• Simon-Tuval T, Shmueli A, Harman-Boehm I. Adherence of patients with type 2 diabetes mellitus to medications: the role of risk preferences. Curr Med Res Opin. 2018;34:345−351. doi:10.1080/03007995.2017.139750629069921
   PubMed Web of Science ®Google Scholar
• Sapkota S, Brien JA, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes – impact on adherence. PLoS One. 2015;10:e0118296. doi:10.1371/journal.pone.011829625710465
   PubMed Web of Science ®Google Scholar
• Emanuel EJ, Emanuel LL. Four models of the physician-patient relationship. JAMA. 1992;267:2221−2226. doi:10.1001/jama.1992.034801600790381556799
   PubMed Web of Science ®Google Scholar